PRAMEF18

Across TCGA pan-cancer cohorts, PRAMEF18 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRAMEF18 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRAMEF18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF18 expression acts as an unfavorable survival marker.

HNSC, PCPG, and SKCM are the cancer types where PRAMEF18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.013	0.768	<.001	48	view →
PCPG	OS	Median	All	0.009	0.946	<.001	12	view →
SKCM	DFS	Median	All	0.094	0.212	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PRAMEF18–HNSC (OS)

Open the HNSC breakdown →